Qutenza (capsaicin) 8% topical system is approved in the US for the treatment of neuropathic pain associated with postherpetic neuralgia and for the treatment of neuropathic pain associated with ...

Grünenthal acquired the global rights to Qutenza ® in 2018 as part of its ... for the treatment of neuropathic pain associated with diabetic peripheral neuropathy (DPN) of the feet in adults.

In Europe, Qutenza®is indicated for the treatment of peripheral ... postherpetic neuralgia and for the treatment of neuropathic pain associated with diabetic peripheral neuropathy (DPN) of the feet in ...